In patients with advanced endometrial cancer, five-year data from the Phase 3 KEYNOTE-775/Study 309 trial revealed a durable survival benefit for KEYTRUDA plus LENVIMA compared to chemotherapy, according to Merck, which is known as MSD outside of the
Pfizer Inc. publicly released updated outcomes from the Phase 2 PHAROS trial examining Braftovi (encorafenib) + Mektovi (binimetinib) in adult subjects with metastatic non-small cell lung cancer (mNSCLC) harboring the BRAF V600E mutation...
The Union Ministry of Health and Family Welfare has suggested a significant modification of the Drugs Rules 1945, which would require Quick Response codes (QR)on labels of all medicines - vaccines, antimicrobials, anticancer, narcotic and...
Recently published data from the FLUNITY-HD Study in The Lancet illustrates that Efluelda provided significantly more protection against hospitalizations than standard-dose influenza vaccines in adults aged 65 and older...
.jpg "WHO Warns India Still has Work to Curb Toxic Cough Syrups")
India continues to be a difficult place regarding the total elimination of toxic cough syrup sales, says a representative of the World Health Organization (WHO). The news comes after 24 children died, at the very least, after taking the Coldrif co...
The Competition Commission of India (CCI) on Tuesday approved Torrent Pharmaceuticals Ltd’s proposed acquisition of a stake in JB Chemicals and Pharmaceuticals, contingent upon certain voluntary modifications submitted by both companies
A new therapy developed by AstraZeneca and Daiichi Sankyo has demonstrated significant success in a major clinical trial targeting an aggressive and difficult-to-treat form of breast cancer, potentially paving the way for regulatory approval
The U.S. Food and Drug Administration (FDA) has authorized TEZSPIRE (tezepelumab-ekko) for the add-on maintenance therapy of poorly managed chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and pediatric patients aged 12 years and above
Eli Lilly and Company has announced strong Phase 3 data for its investigational oral GLP-1 therapy Orforglipron from ACHIEVE-2 and ACHIEVE-5 trials, which could potentially lay the groundwork for a new treatment standard in type 2 diabetes...
On Monday AbbVie proclaimed that its newest arthritis medication, Rinvoq, outperformed the company’s established best-selling product Humira in a head-to-head clinical study. These findings represent a substantial achievement for AbbVie as it...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")